Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial.

Maria Assunta Zocco, Veronica Ojetti, Giovanni Cammarota, Giovanni Battista Gasbarrini, Antonio Gasbarrini, Enrico Celestino Nista, Marcello Candelli, Filippo Cremonini, Immacolata Alessia Cazzato, Simona Di Caro, Maurizio Gabrielli, Luca Santarelli, Emilia Carloni

Risultato della ricerca: Contributo in rivistaArticolo in rivista

97 Citazioni (Scopus)

Abstract

BACKGROUND: Levofloxacin has been shown to be effective in Helicobacter pylori eradication. Two 10-day levofloxacin-based triple therapies were compared with standard 7- and 14-day quadruple regimens in second-line treatment. METHODS: Two hundred and eighty consecutive patients who failed to respond to standard triple therapy (clarithromycin, amoxicillin, rabeprazole) were randomly assigned to four groups: (1) levofloxacin 500 mg o.d., amoxicillin 1 g b.d., rabeprazole 20 mg b.d. for 10 days (LAR, n = 70); (2) levofloxacin 500 mg o.d., tinidazole 500 mg b.d., rabeprazole 20 mg b.d. for 10 days (LTR, n = 70); (3) tetracycline 500 mg q.d.s., metronidazole 500 mg t.d.s., bismuth salt 120 mg q.d.s., rabeprazole 20 mg b.d. for 7 days (7TMBR, n = 70); and (4) for 14 days (14TMBR, n = 70). Helicobacter pylori status and side-effects were assessed 6 weeks after treatment. RESULTS: The eradication rate was 94% in the LAR group and 90% in the LTR group in both intention-to-treat and per protocol analyses. Helicobacter pylori eradication was achieved in 63 and 69% of the 7TMBR group and in 69 and 80% of the 14TMBR group in intention-to-treat and per protocol analysis, respectively. Side-effects were significantly lower in the LAR and LTR groups than in the 14TMBR group. CONCLUSION: Ten-day levofloxacin-based therapies are better than standard quadruple regimens as second-line option for H. pylori eradication.
Lingua originaleEnglish
pagine (da-a)627-633
Numero di pagine7
RivistaALIMENTARY PHARMACOLOGY & THERAPEUTICS
Stato di pubblicazionePubblicato - 2003

Keywords

  • H Pylori
  • levofloxacin

Fingerprint Entra nei temi di ricerca di 'Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial.'. Insieme formano una fingerprint unica.

Cita questo